Table 1.
Demographic data regarding the laryngeal and oropharyngeal cancer groups of patients. Results are reported as value (%) and mean value ± standard deviation, as appropriate.
| Laryngeal cancer group | p-value | ||
|---|---|---|---|
| TOELS = 40 (50.1) | TOLMS = 39 (49.9) | ||
| Age | 71.7 ± 8.6 | 71.2 ± 12.3 | 0.73 |
| Gender | |||
| Male | 31 (80.0%) | 32 (80.0%) | 0.95 |
| Female | 9 (20.0%) | 7 (20.0%) | |
| Laryngoscore | 4.9 ± 1.8 | 4.7 ± 1.8 | 0.69 |
| pT classification | |||
| pT1 | 38 (95.0%) | 27 (69.2%) | 0.025 |
| pT2 | 2 (5.0%) | 4 (10.2%) | |
| pT3 | 0 (0.0%) | 5 (12.8%) | |
| Subsite | |||
| Glottis | 40 (100.0%) | 31 (79.5%) | 0.002 |
| Supraglottis | 0 (0%) | 9 (20.5%) | |
| Oropharyngeal cancer group | |||
| TOELS = 16 (37.2) | (CT)RT = 27 (62.8) | ||
| Age | 71.5 ± 10.7 | 66.5 ± 10.9 | 0.18 |
| Gender | |||
| Male | 14 (93.7%) | 16 (62.9%) | 0.031 |
| Female | 1 (6.3%) | 11 (36.1%) | |
| P16 positivity | 6 (37.5%) | 21 (77.8%) | 0.062 |
| Stage p16+ | |||
| Stage I | 5 (83.3%) | 5 (23.8%) | 0.99 |
| Stage II | 1 (16.7%) | 16 (76.2%) | |
| Stage p16− | |||
| Stage II | 1 (14.3%) | 0.99 | |
| Stage III | 2 (28.6%) | ||
| Stage IVA | 3 (42.9%) | 2 (40.0%) | |
| Stage IVB | 1 (14.3%) | 3 (60.0%) | |
TOELS, transoral exoscopic laryngeal surgery; TOLMS, transoral laryngeal microsurgery; (CT)RT, (chemo)radiotherapy.